The most common non-skin cancer in males is prostate cancer, which is also the leading cause of cancer-related death. A commonly used prostate specific antigen (PSA) blood test is used to detect prostate cancer early, and a biopsy is utilised to confirm the diagnosis. Prostate cancer is asymptomatic in its early stages, has a wide range of clinicopathologic and clinical traits, and is classified as an indolent cancer type by a big percentage of men. As a result, developing a customised approach for early detection, disease categorization (indolent vs. aggressive), and treatment response prediction for prostate cancer is crucial. The current study analyses the therapeutic value of biomarkers in prostate cancer care based on current understanding of available diagnostic and prognostic molecular markers in prostate cancer. Prostate cancer biomarker development has advanced dramatically, thanks in great part to advances in genetic technologies. For serum (4K, phi), urine (Progensa, T2-ERG, ExoDx, SelectMDx), and tumour tissue, a wide range of diagnostic and prognostic assays has arisen (ConfirmMDx, Prolaris,Oncoytype DX, Decipher). These assays have opened up new possibilities for better prostate cancer diagnosis, prognosis, and therapy choices. While these advancements present great prospects, they also present significant hurdles in terms of selecting and implementing these tests into the prostate cancer patient care continuum.
Author(S) Details
Indu Kohaar
The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), Inc., Bethesda, MD 20817, USA and Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD 20814, USA.
Gyorgy Petrovics
The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), Inc., Bethesda, MD 20817, USA and Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD 20814, USA.
Shiv Srivastava
Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD 20814, USA
View Book:- https://stm.bookpi.org/NVBS-V8/article/view/5376
No comments:
Post a Comment